Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpa... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemothe... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy,and Pharmacokinetics o... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety an... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or ... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muval... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muval... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More